FTH FAETH THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, FAETH THERAPEUTICS INC reported revenue of n/a, net income of −$16.0M and diluted EPS of −$2.84; for the fiscal year ended December 2025 revenue was n/a.
FTH annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$22.3M, net income −$21.1M (margin n/a), EPS −$16.72
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$32.6M, net income −$30.2M (margin n/a), EPS −$24.01
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$37.1M, net income −$34.1M (margin n/a), EPS −$1.22
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$50.2M, net income −$48.6M (margin n/a), EPS −$1.58
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$37.5M, net income −$36.8M (margin n/a), EPS −$1.33
FTH quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$16.0M, EPS −$2.84
- Quarter ended Mar 31, 2026: revenue n/a, net income −$170M, EPS −$131.45
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$4.72M, EPS −$3.74
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.57M, EPS −$3.62
- Quarter ended Jun 30, 2025: revenue n/a, net income −$4.94M, EPS −$3.91
- Quarter ended Mar 31, 2025: revenue n/a, net income −$6.86M, EPS −$5.45
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$7.77M, EPS −$12.23
- Quarter ended Sep 30, 2024: revenue n/a, net income −$7.25M, EPS −$5.77
- Quarter ended Jun 30, 2024: revenue n/a, net income −$7.14M, EPS −$5.69
- Quarter ended Mar 31, 2024: revenue n/a, net income −$7.99M, EPS −$0.32
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$7.41M, EPS −$0.30
- Quarter ended Sep 30, 2023: revenue n/a, net income −$7.12M, EPS −$0.28
- Quarter ended Jun 30, 2023: revenue n/a, net income −$9.39M, EPS −$0.31
- Quarter ended Mar 31, 2023: revenue n/a, net income −$10.2M, EPS −$0.33
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$12.2M, EPS −$0.40
- Quarter ended Sep 30, 2022: revenue n/a, net income −$13.4M, EPS −$0.44
- Quarter ended Jun 30, 2022: revenue n/a, net income −$10.5M, EPS −$0.34
- Quarter ended Mar 31, 2022: revenue n/a, net income −$12.4M, EPS −$0.40
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$9.37M, EPS −$0.27
- Quarter ended Sep 30, 2021: revenue n/a, net income −$9.69M, EPS −$0.32
FTH cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$20.5M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$24.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$32.0M, share buybacks $10.4M
- Fiscal year ended Dec 2022: operating cash flow −$39.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$30.3M, share buybacks n/a
FTH balance sheet
- Jun 30, 2026: cash $26.9M, total assets $189M, total liabilities $9.58M, shareholders' equity $173M
- Mar 31, 2026: cash $152M, total assets $205M, total liabilities $14.2M, shareholders' equity −$137M
- Dec 31, 2025: cash $8.67M, total assets $22.9M, total liabilities $4.31M, shareholders' equity $18.6M
- Sep 30, 2025: cash $10.6M, total assets $27.6M, total liabilities $4.58M, shareholders' equity $23.0M
- Jun 30, 2025: cash $12.6M, total assets $31.8M, total liabilities $4.47M, shareholders' equity $27.3M
- Mar 31, 2025: cash $9.88M, total assets $38.3M, total liabilities $6.29M, shareholders' equity $32.0M
- Dec 31, 2024: cash $9.99M, total assets $45.4M, total liabilities $6.98M, shareholders' equity $38.4M
- Sep 30, 2024: cash $19.1M, total assets $53.3M, total liabilities $7.48M, shareholders' equity $45.8M
Is FTH profitable?
No. FAETH THERAPEUTICS INC lost $196M over the last four quarters.
What is FTH's EPS?
Diluted earnings per share over the last four quarters were −$141.65; −$2.84 in the latest quarter.